Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromes

Cancer

Volumn 107, Issue 12, 2006, Pages 2807-2816

  Giraldo, Pilar ^a   Nomdedeu, Benet ^b   Loscertales, Javier ^c   Requena, Carmen ^d   De Paz, Raquel ^e   Tormo, Mar ^f   Navarro, Pilar ^g   Benedit, Patricia ^h   Gasquet, José Antonio ^h  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d Ubeda Hospital   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f Hospital Clinic   (Spain)

^g Haematology Services   (Spain)

^h Amgen SA   (Spain)

Author keywords

Anemia; Darbepoetin ; Erythroid response; Myelodysplastic syndrome

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COMORBIDITY; FEMALE; GASTROINTESTINAL DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SPAIN;

EID: 33845563409     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22343     Document Type: Article

References (53)

1. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006;81:104-130.
2. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340:1649-1660.
3. The Myelodysplastic Syndromes Foundation. Available at URL: http://www.mds-foundation.org. Accessed July 15, 2006.
4. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358-367.
5. Germing U, Strupp C, Kundgen A, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004;89:905-910.
6. Bauduer F, Ducout L, Dastugue N, Capdupuy C, Renoux M. Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leukemia Res. 1998;22:205-208.
7. Maynadie M, Verret C, Moskovtchenko P, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996;74:288-290.
8. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994;87:743-745.
9. Radlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol. 1995;54:153-156.
10. Iglesias Gallego M, Sastre Moral JL, Gayoso DP, Garcia CA, Ros FS, Mayan Santos JM. Incidence and characteristics of myelodysplastic syndromes in Ourense (Spain) between 1994-1998. Haematologica. 2003;88:1197-1199.
11. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leukemia Res. 2003;27:95-120.
12. Belli C, Acevedo S, Bengio R, et al. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Haematologica. 2002;87:9-16.
13. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536-538.
14. Malcovati L. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594-7603.
15. Malcovati L. A type 11 mutation (Glu 117 stop) induction of allele-specific MRNA degradation and factor XI deficiency. Haematologica. 2005;90:1716-1718.
16. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
17. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
18. Gardin C, Fenaux P. Supportive care including growth factors in myelodysplastic syndromes. Rev Clin Exp Hematol. 2004;8:E3.
19. Spiriti MA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005;84:167-176.
20. Grossi A. Management of cancer anemia. J Chemother. 2004;16(suppl 4):112-116.
21. Rizzo JD, Seidenfeld J, Piper M, Aronson N, Lichtin A, Littlewood TJ. Erythropoietin: a paradigm for the development of practice guidelines. Hematology Am Soc Hematol Educ Program. 2001;10-30.
22. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica. 2002;87: 1209-1221.
23. Charuruks N, Voravud N, Limpanasithikul W. Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients. J Clin Lab Anal. 2001;15:260-266.
24. Cazzola M, Ponchio L, Pedrotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica. 1996;81:434-441.
25. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998;103:1070-1074.
26. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99:344-351.
27. Stasi R, Brunetti M, Bussa S, et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res. 1997;3:733-739.
28. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol. 1995;89:831-837.
29. Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol. 2002;118:174-180.
30. Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol. 2002;68:180-185.
31. Rodriguez JN, Dieguez JC, Muniz R, et al. Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study [in Spanish]. Sangre (Barcelona). 1994;39:435-439.
32. Aul C, Arning M, Runde V, Schneider W. Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leukemia Res. 1991;15:571-575.
33. Stasi R, Brunetti M, Terzoli E, Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood. 2002;99:1578-1584.
34. [No authors listed.] Pretreatment erythropoietin levels cannot be used to predict individual response to epoetin alfa in anaemic cancer patients. Curr Med Res Opin. 2005;21(suppl 2):S19-S21.
35. Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist. 2003;8:99-107.
36. Vansteenkiste J, Rossi G, Foote M. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther. 2003;3:501-518.
37. Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol. 2005;16:1921-1927.
38. Mannone L, Gardin C, Quarre M, et al. High response rate to darbepoetin alfa in "low risk" MDS: results of a phase II study [abstract]. Blood. 2004;104:24a.
39. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol. 2005;128:204-209.
40. Gabrilove J, Paquette R, Lyons R, et al. A phase 2, single-arm, open-label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome. 47th Annual Meeting of the American Society of Hematology Annual Meeting, Atlanta, Georgia, December 10-13, 2005. Blood. 2005;106: 713a.
41. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
42. Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. J Support Oncol. 2005;3:419-426.
43. Cersosimo RJ, Jacobson DR. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother. 2006;40:58-65.
44. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Eur J Haematol 2003;120:1037-1046.
45. Hellstrom-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology Am Soc Hematol Educ Program. 2005;161-166.
46. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106:803-811.
47. National Comprehensive Cancer Network, Inc. Myelodysplastic Syndromes. NCCN Practice Guidelines in Oncology, version 3 [electronic citation]. 2006:MS4-MS5.
48. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120:187-200.
49. Balleari E, Rossi E, Clavio M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol. 2006;85:174-180.
50. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996;87:4076-4081.
51. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68-75.
52. Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol. 2000;109:367-375.
53. Remacha AF, Arrizabalaga B, Villegas A, et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica. 1999;84:1058-1064.